UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported):                April 7, 2017               

 

NORTHWEST BIOTHERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 001-35737 94-3306718

(State or other jurisdiction of

incorporation or organization)

(Commission File Number)

(IRS Employer

Identification No.)

 

4800 Montgomery Lane, Suite 800

Bethesda, MD 20814

(Address of principal executive offices)

 

(204) 497-9024
(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

 

 

  

Item 8.01. OTHER EVENTS

 

Northwest Biotherapeutics, Inc. (the “Company”) has received shareholder inquiries asking for re-confirmatio n that the partial hold on screening for enrollment in the Company’s Phase III trial was lifted as described in the Company’s prior announcement on February 6, 2017, as the Company’s most recent Prospectus Supplement did not contain this update.  The Company re-confirmed that the FDA’s partial hold was lifted as previously reported. 

 

 

SIGNATURES

 

PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED.

 

 

  NORTHWEST BIOTHERAPEUTICS, INC.  
       
       
Date: April 7, 2017 By:  /s/ Linda F. Powers  
 

Name: Linda F. Powers

Title: Chief Executive Officer

 

 

 

 

 

Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Northwest Biotherapeutics (QB) Charts.
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Northwest Biotherapeutics (QB) Charts.